Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study

被引:26
|
作者
Fu, Shau-Huai [1 ,2 ,3 ]
Wang, Chen-Yu [4 ,5 ,6 ]
Hung, Chih-Chien [1 ]
Lee, Chia-Che [3 ]
Yang, Rong-Sen [3 ]
Huang, Chuan-Ching [3 ]
Farn, Chui-Jia [3 ]
Lin, Wei-Hsin [3 ]
Chen, Ho-Min [7 ]
Hsiao, Fei-Yuan [4 ,5 ,8 ]
Lin, Jou-Wei [9 ]
Li, Chung-Yi [2 ,10 ,11 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Orthoped, Yunlin Branch, Touliu, Yunlin, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 138 Sheng Li Rd, Tainan 704, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Orthoped, Taipei, Taiwan
[4] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[5] Natl Taiwan Univ, Coll Med, Grad Inst Clin Pharm, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Pharm, Yunlin Branch, Touliu, Yunlin, Taiwan
[7] Natl Taiwan Univ, Hlth Data Res Ctr, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Cardiovasc Ctr, YunlinBranch, Touliu, Yunlin, Taiwan
[10] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan
[11] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung, Taiwan
关键词
osteoporosis; denosumab; bisphosphonate; discontinuation; fractures; VERTEBRAL FRACTURES; DENOSUMAB DISCONTINUATION; POSTMENOPAUSAL WOMEN; TRIAL; PERSISTENCE; REDUCTION; THERAPY; MEN;
D O I
10.1111/joim.13354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background To compare the risks of major osteoporotic, vertebral, and non-vertebral fractures between patients who discontinued anti-osteoporosis medications. Methods We conducted a comparative effectiveness study with a nationwide population-based cohort study design. Patients aged >= 50 years admitted between 2012 and 2015 for incident hip fractures and receiving denosumab or bisphosphonates with sufficient compliance for at least 1 year were included. Patients were categorized into persistent or non-persistent denosumab or bisphosphonates users based on their subsequent use pattern. The main outcomes were subsequent hospitalizations for a major osteoporotic, vertebral or non-vertebral fracture. Multivariate, time-varying Cox proportional hazards model was used to evaluate the risk of major outcomes. Results Compared with persistent denosumab users, non-persistent denosumab users had a significantly higher risk of major osteoporotic fractures (hazard ratio [HR] = 1.60; 95% confidence interval [CI], 1.20-2.14), vertebral fractures (HR = 2.18; 95% CI, 1.46-3.24) and death (HR = 3.57; 95%CI, 2.63-4.84). However, the increased risk of fracture was not found in both persistent and non-persistent bisphosphonates users. Noteworthy, the increased risk of vertebral fractures in non-persistent denosumab users was more pronounced within 1 year post-discontinuation (HR = 2.90; 95% CI, 1.77-4.74) and among patients who discontinued from 2-year denosumab therapy (HR = 3.58; 95% CI, 1.74-7.40). Discussion Discontinuation of denosumab resulted in an increased risk of major osteoporotic fractures, especially vertebral fractures. The increased risk tends to reveal within 1 year post-discontinuation and be greater after a longer treatment duration. Notably, only fracture with hospitalization was identified as our research outcome, the real risk of osteoporotic fracture post discontinuation is believed to be higher, especially for vertebral fracture.
引用
收藏
页码:1194 / 1205
页数:12
相关论文
共 50 条
  • [1] Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study
    Wu, Y. -C.
    Chen, S.
    Wu, P. -L.
    Tsou, H. -K.
    Wei, J. C. -C.
    JOURNAL OF INTERNAL MEDICINE, 2022, 291 (03) : 384 - 385
  • [2] Timing of anti-osteoporosis medications initiation after a hip fracture affects the risk of subsequent fracture: A nationwide cohort study
    Wang, Chen-Yu
    Fu, Shau-Huai
    Yang, Rong-Sen
    Chen, Liang-Kung
    Shen, Li-Jiuan
    Hsiao, Fei-Yuan
    BONE, 2020, 138
  • [3] Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study
    Lyu, Houchen
    Yoshida, Kazuki
    Zhao, Sizheng S.
    Wei, Jie
    Zeng, Chao
    Tedeschi, Sara K.
    Leder, Benjamin Z.
    Lei, Guanghua
    Tang, Peifu
    Solomon, Daniel H.
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (07) : 516 - +
  • [4] Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture
    Wang, Pei-wen
    Li, Yi-zhong
    Zhuang, Hua-feng
    Yu, Hai-ming
    Cai, Si-qing
    Xu, Hao
    Chen, Zhen-hui
    Lin, Jin-kuang
    Yao, Xue-dong
    ORTHOPAEDIC SURGERY, 2019, 11 (05) : 777 - 783
  • [5] Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study
    Carbonell-Abella, C.
    Pages-Castella, A.
    Javaid, M. K.
    Nogues, X.
    Farmer, A. J.
    Cooper, C.
    Diez-Perez, A.
    Prieto-Alhambra, D.
    CALCIFIED TISSUE INTERNATIONAL, 2015, 97 (06) : 535 - 541
  • [6] Access to Anti-osteoporosis Medication after Hip Fracture in Korean Elderly Patients
    Yu, Yun Mi
    Lee, Ju-Yeun
    Lee, Euni
    MATURITAS, 2017, 103 : 54 - 59
  • [7] Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS)
    Riska, Brit Solvor Lyse
    Gunnes, Nina
    Stigum, Hein
    Finnes, Trine E.
    Meyer, Haakon E.
    Omsland, Tone K.
    Holvik, Kristin
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (08) : 1369 - 1379
  • [8] Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study
    C. Carbonell-Abella
    A. Pages-Castella
    M. K. Javaid
    X. Nogues
    A. J. Farmer
    C. Cooper
    A. Diez-Perez
    D. Prieto-Alhambra
    Calcified Tissue International, 2015, 97 : 535 - 541
  • [9] Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010
    Klop, C.
    Gibson-Smith, D.
    Elders, P. J. M.
    Welsing, P. M. J.
    Leufkens, H. G. M.
    Harvey, N. C.
    Bijlsma, J. W. J.
    van Staa, T. -P.
    de Vries, F.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (07) : 1919 - 1928
  • [10] Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis
    Wang, Chen-Yu
    Wu, Chih-Hsing
    Chen, Ho-Min
    Lin, Jou-Wei
    Hsu, Chih-Cheng
    Chang, Yin-Fan
    Tai, Ta-Wei
    Fu, Shau-Huai
    Hwang, Jawl-Shan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 : S92 - S100